Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

  • Mithra grants exclusive 10-year license to Megalabs for commercialization of vaginal contraceptive ring in Argentina, Paraguay and the Dominican Republic
  • Product to be manufactured at Mithra CDMO facility in Belgium
  • Agreement follows licensing deals for Myring™ with international market leaders in the U.S., Europe, Russia, Australia, Middle East and Chile
Liege, Belgium, 25 April 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with the pharmaceutical group Megalabs for the commercialization of its vaginal contraceptive ring Myring™ in Latin America and South America. Based in Uruguay, Megalabs develops a wide range of market-leading pharmaceutical products in twenty Latin American countries.